Orexigen Therapeutics, Inc. Uncategorized Contracts & Agreements
53 Contracts & Agreements
- Debtors Modified Amended Plan of Liquidation (Filed With SEC on May 23, 2019)
- INVESTOR RIGHTSAGREEMENT BY AND AMONG OREXIGEN THERAPEUTICS, INC., BAUPOST GROUP SECURITIES, L.L.C., AND THE OTHERINVESTORS PARTY HERETO DATED AS OF MARCH 15, 2016 TABLE OF... (Filed With SEC on March 15, 2016)
- EXHIBIT A OPTION GRANTS (Filed With SEC on June 26, 2015)
- OREXIGEN THERAPEUTICS, INC. Recoupment Policy Acknowledgement (Filed With SEC on April 25, 2014)
- EXHIBIT A AMENDMENT TO OREXIGEN THERAPEUTICS, INC. 2007 EQUITY INCENTIVEAWARD PLAN (Filed With SEC on September 23, 2013)
- OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT FEBRUARY 15, 2013 (Filed With SEC on August 7, 2013)
- OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 4 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT FEBRUARY 15, 2013 (Filed With SEC on August 7, 2013)
- OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 3 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT MARCH 15, 2012 (Filed With SEC on March 16, 2012)
- OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT NOVEMBER 1, 2011 (Filed With SEC on November 3, 2011)
- OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT NOVEMBER 1, 2011 (Filed With SEC on November 1, 2011)
- OREXIGEN THERAPEUTICS, INC. 2007 EQUITY INCENTIVEAWARD PLAN ARTICLE 1 PURPOSE (Filed With SEC on March 2, 2010)
- OREXIGEN THERAPEUTICS, INC. INDEPENDENT DIRECTORCOMPENSATION POLICY (Filed With SEC on March 2, 2010)
- OREXIGEN THERAPEUTICS, INC. 2007 EQUITY INCENTIVEAWARD PLAN ARTICLE 1 PURPOSE (Filed With SEC on November 24, 2009)
- [Remainder of This Page Intentionally Left Blank] (Filed With SEC on March 13, 2009)
- RESIGNATION AGREEMENT (Filed With SEC on December 5, 2008)
- Product Candidate (Filed With SEC on January 14, 2008)
- Exhibit No (Filed With SEC on January 7, 2008)
- Entry into a Material Definitive Agreement (Filed With SEC on December 14, 2007)
- Entry into a Material Definitive Agreement (Filed With SEC on December 14, 2007)
- Number of Shares (Filed With SEC on November 8, 2007)
- Exhibit No (Filed With SEC on September 18, 2007)
- Exhibit No (Filed With SEC on August 28, 2007)
- Exhibit No (Filed With SEC on July 3, 2007)
- Exhibit No (Filed With SEC on June 20, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on February 16, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on February 16, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on February 16, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on February 16, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on January 23, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on January 23, 2007)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on December 19, 2006)
- On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on December 19, 2006)
